

HA130 Disposable Hemoperfusion Cartridge Properties

Adsorbent Volume (mL)	130
Biocompatibility	Tested as required in ISO10993
Adsorbent Material	Double Cross-linked Styrene-divinylbenzene Copolymers
Housing Material	Polycarbonate
Sterilization Method	Irradiation Sterilization
Unit Package	195±2mm(L)*110±2mm(W)*110.5±2mm(H)

*Contraindications, Warnings and Precautions refer to Instructions For Use.

JAFRON - Global Manufacturer and Supplier of Adsorption Columns



Jafron Headquarters



CE



ISO 9001



EN ISO 13485

References

- 1.Lekawanvijit, Suree , A. R. Kompa , and H. Krum . American Journal of Physiology Renal Physiology 311.1(2016):ajprenal.00348.2015.
- 2.Shun-Jie Chen, et al. Int J Artif Organs 2011; 34 (4): 339-347.
- 3.Yang Xiaodan, Continuing Medical Education, March, 2019, Vol. 33, No.3.
- 4.Guo Ai-hua, et al. Journal of Clinical Rehabilitative Tissue Engineering Research March 19, 2011 Vol.15, No.12.
- 5.Jing Zhang, et al. Int J Clin Exp Med 2016;9(5):8563-8568.
- 6.Yu Yin, et al. Journal of Hainan Medical University (2015)57-60.
- 7.Li-ying Miao, et al. Experimental And Therapeutic Medicine 7: 947-952, 2014.
- 8.Yan Hong Gu ,et al. The International Journal of Artificial Organs 1-7, 2019.
- 9.Zhu Feng, et al. Chinese and Foreign Medical Research Vol.17, No.6 February, 2019.
- 10.Duan Bin, et al. Med J West China, February 2019, Vol. 31, No.2.
- 11.He Qi, et al. Chinese Journal of Clinical Research, February 2018, Vol. 31, No.2.
- 12.Zhang Yu, et al. Shanghai Medicine, November 2018, Vol.39, No.21.
- 13.Yu Jirong, et al. J Southeast Univ(Med Sci Edi) Dec. 2018, Vol.37, No.6:1018-1022.
- 14.Jun Tang, et al. Journal of Hainan Medical University 2017; 23(4): 74-78.
- 15.Li Xiaolei, et al. Journal of Practical Medicine 2017, 33(20).
- 16.Ji Xu, et al. Journal of Internal Intensive Medicine 2017, 23(3).
- 17.Pomarè Montin, et al. Blood Purif 2018;46:187-195.
- 18.Wang, Xin Fang , et al. J Clin Lab+ Anal. 2019;33:e22713 .
- 19.Huu, Dung Nguyen, et al. Blood Purification: 1-8.
- 20.He, Haidong , Y. Xie. BioMed Research International 2020. 4 (2020):1-8.
- 21.Li, Jibo et al. Proceedings of Anticancer Research 3.5 (2019).
- 22.Su, Jing, et al. BOLETIN DE MALARIOLOGIA Y SALUD AMBIENTAL 2020, Vol. 60 (1): 235-239.
- 23.Lekawanvijit, S. Am J Physiol Renal Physiol. 2016;311(1):F52-F62 .
- 24.Amela, Beciragic , et al. Nephrology Dialysis. Transplantation Supplement_3:Supplement_3.
- 25.Panichi, Vicenzo. 57 th ERA-EDTA Congress, 6 June 2020, Online. lecture.
- 26.Jiang, Gengru. 57 th ERA-EDTA Congress, 6 June 2020, Online. lecture.

CY-HA130OB-01-10-2021-EN

 **Jafron**

Stock Abbreviation: JFSW
Stock Code: 300529

HD/HDF+HP

Improve Life Quality for MHD Patients^[1-26]



HA130

Disposable Hemoperfusion Cartridge

20 years in blood purification clinical practices
Widely used in more than 80 countries
More than 5 million treatments per year

CE 0197




JAFRON BIOMEDICAL CO., LTD.

Address: No. 98, Technology Sixth Road, High-tech Zone, Zhuhai City, 519085, Guangdong, China.
Tel: +86 (756) 3689708
E-mail: overseatrade@jafron.com
Website: www.jafron.com

(For Internal Use)


Uremic toxins could be classified as small water-soluble compounds or groups, protein-bound compounds and middle molecules^[1]. The removal of small water-soluble compounds has been largely improved with the development of dialysis membrane. However, the removal of protein-bound toxins and middle molecules is still unsatisfying. HA130 hemoperfusion therapy provides a new regimen for ESRD complications.

Efficiency & Safety



Neutral macroporous 3D adsorptive resin can adsorb middle molecules and protein-bound uremic toxins.

- High mechanical strength of adsorbents
- Large adsorptive surface area
- Accurate adjustment of pore size distribution



Good biocompatibility^[16]


- Advanced coating method
- Optimized hemodynamics

With particle filter

- Prevent particle detachment into human body


Adsorption Therapy Applications[△]

According to clinical practices, hemoperfusion therapy can be applied in the listed conditions.



Therapy Operation Mode[△] : HD/HDF +HP

With the adsorptive capability of removing uremic toxins, HD/HDF+HP provides a new therapy to remove uremic toxins in ESRD.




[△]For detailed information, please visit www.jafron.com.


HD/HDF+HP Provides a New Therapy for ESRD Patients

● Remove Protein-bound Toxins^[25]

Indoxyl Sulphate*




P-cresyl Sulphate*






*Unpublished data







Protein-bound uremic toxins are associated with shorter renal survival.



● Remove Middle-molecule Toxins^[18]



● Improve Life Quality^[18]




*P<0.05 vs Before treatment
#P<0.05 vs HD group
&P<0.05 vs HDF group


HD group: 3 times every week
HDF group: 1 time HF & 2 times HD every week
HP group: 1 time HP & 5 times HD every 2 weeks

● Reduce All-cause Mortality and Cardiovascular Mortality^[26]

All-cause Mortality*



Cardiovascular Mortality*



*Unpublished data